MS News that Caught My Eye Last Week: Reaction to SPMS DMT Approval, Ozanimod’s FDA Application, Caregiving Partnerships, a New Preventive Medication?
MS Patient Groups React Favorably to Mayzent Approval, But Question Therapy’s Price Tag The approval of this medication is very good news. However, as the headline indicates, it comes with a relatively hefty cost. It’s approved for active secondary progressive multiple sclerosis (SPMS), and many of us have SPMS…